Amprenavir [clinicaltrials_resource:77f7663aa13ec13d35fabfa3663dca44]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients [clinicaltrials:NCT00000912]Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV [clinicaltrials:NCT00000940]A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir [clinicaltrials:NCT00001095]Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz [clinicaltrials:NCT00001758]Drug Interactions Among Anti-HIV Agents [clinicaltrials:NCT00001766]Once-Daily Drug Regimen for HIV-Infected Patients [clinicaltrials:NCT00001968]An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen [clinicaltrials:NCT00002205]A Study of a Combination of Four Drugs in Patients With Recent HIV Infection [clinicaltrials:NCT00002233]A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults [clinicaltrials:NCT00002239]A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients [clinicaltrials:NCT00002245]A Study of Amprenavir in HIV-Infected Patients [clinicaltrials:NCT00002405]A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications [clinicaltrials:NCT00002417]Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment [clinicaltrials:NCT00002419]A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir [clinicaltrials:NCT00002423]Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers [clinicaltrials:NCT00005762]Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients [clinicaltrials:NCT00006617]Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor [clinicaltrials:NCT00038519]Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART [clinicaltrials:NCT00038532]Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients [clinicaltrials:NCT00056641]Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure. [clinicaltrials:NCT00196625]Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV [clinicaltrials:NCT00307502]Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults [clinicaltrials:NCT02182765]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Amprenavir [clinicaltrials_resource:77f7663aa13ec13d35fabfa3663dca44]
Bio2RDF identifier
77f7663aa13ec13d35fabfa3663dca44
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:77f7663aa13ec13d35fabfa3663dca44
identifier
clinicaltrials_resource:77f7663aa13ec13d35fabfa3663dca44
title
Amprenavir
@en
type
label
Amprenavir [clinicaltrials_resource:77f7663aa13ec13d35fabfa3663dca44]
@en